OverviewSuggest Edit
Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA and with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, the Company is building one of the most robust oncology pipelines in the industry.
| Type | Public | |
| Founded | 2000 | |
| HQ | Cambridge, US | Map |
| Website | merrimack.com | |
| Employee Ratings | More |
Key People/Management at Merrimack Pharmaceuticals
Richard Peters
Merrimack Pharmaceuticals Office Locations
Merrimack Pharmaceuticals Financials and Metrics
Merrimack Pharmaceuticals Revenue
| USD | |
|---|---|
Net income (FY, 2018) | (40.5m) |
Market capitalization (18-Mar-2019) | 94.5m |
Closing stock price (18-Mar-2019) | 7.1 |
Cash (31-Dec-2018) | 20.1m |
EV | 89.3m |
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 105.5m | 66.9m | 77.8m | 100.3m | 28.8m | 33.7m | 56.4m | 48.2m | 21.5m | 36.5m | 17.2m | 135.5m | 107.2m | 34.3m | 22.5m |
Accounts Receivable | 8.8m | 12.2m | 6.6m | 2.6m | 4.2m | 1.8m | 2.1m | 15.6m | 19.3m | 22.2m | 43.0k | 43.0k | 190.0k | ||
Inventories | 8.1m | 12.3m | 14.8m | ||||||||||||
Current Assets | 200.3m | 138.9m | 103.8m | 162.1m | 99.3m | 74.9m | 70.9m | 160.7m | 119.0m | 89.6m | 46.3m | 141.6m | 115.6m | 77.1m | 61.7m |
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (98.3m) | (27.8m) | (46.0m) | (74.1m) | (34.4m) | (57.3m) | (99.7m) | (38.7m) | (89.6m) | (119.9m) | (30.2m) | 480.7m | 483.8m | (17.8m) | (35.6m) |
Depreciation and Amortization | 1.9m | 886.0k | 2.2m | 2.8m | 2.1m | 4.3m | 1.5m | 3.0m | 5.2m | 1.2m | 2.1m | 2.8m | 1.2m | 2.3m | |
Inventories | (4.4m) | (8.4m) | (10.7m) | ||||||||||||
Cash From Operating Activities | (67.7m) | (31.4m) | (64.2m) | (3.1m) | (59.7m) | (102.0m) | (53.5m) | (104.4m) | (139.3m) | (10.2m) | (95.5m) | (121.1m) | (17.3m) | (33.6m) |
| USD | Y, 2018 |
|---|---|
EV/CFO | -1.4 x |
Financial Leverage | 1.5 x |
Merrimack Pharmaceuticals Online and Social Media Presence
1.12k Twitter followers
Merrimack Pharmaceuticals has 1.12k Twitter Followers. The number of followers has increased 0.2% month over month and decreased 0.5% quarter over quarter
Merrimack Pharmaceuticals News and Updates
 Merrimack Pharmaceuticals Frequently Asked Questions
When was Merrimack Pharmaceuticals founded?
Merrimack Pharmaceuticals was founded in 2000.
Who are Merrimack Pharmaceuticals key executives?
Merrimack Pharmaceuticals's key executives are Richard Peters.
How many employees does Merrimack Pharmaceuticals have?
Merrimack Pharmaceuticals has 27 employees.
Who are Merrimack Pharmaceuticals competitors?
Competitors of Merrimack Pharmaceuticals include Heidelberg Pharma, MEI Pharma and Oncopeptides.
Where is Merrimack Pharmaceuticals headquarters?
Merrimack Pharmaceuticals headquarters is located at One Kendall Square, Binney St, Cambridge.
Where are Merrimack Pharmaceuticals offices?
Merrimack Pharmaceuticals has an office in Cambridge.
How many offices does Merrimack Pharmaceuticals have?
Merrimack Pharmaceuticals has 1 office.